Shao et al. similarly explored the effect of the effect of HER2-low on NAC efficacy in different states of HR, and they made adjustments to the definition of pCR, and their results indicated that HER2-low might be related to the pCR of BC patients treated with NAC, but different HR statuses and criteria for the definition of pCR need to be taken into account at the same time (Schettini et al., 2021). Here, ERBB2 is linked to breast cancer.